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Heart failure (HF), an epidemic of the XXI cen-
tury, is a leading cause of hospitalizations and mor-
tality in developed countries. Recent data indicate
that 1–2% of an adult population suffers from HF,
with the prevalence being as high as 10% in elder-
ly. With over 500,000 new cases recognized yearly
in the US, admissions for “de novo” HF and read-
missions for pump failure deterioration constitute
one of the leading causes of hospitalizations. De-
spite advancement in modern treatment, and some
improvement in survival observed during last de-
cade, the diagnosis of HF carries a very poor prog-
nosis for patients, and implicates substantial finan-
cial impact on healthcare system [1–3]. Recognition
of HF implicates management strategies including
pharmacotherapy, electrotherapy and lifestyle
change. These treatment strategies are aimed to
decrease symptoms, and number of readmissions
for HF worsening, prevent life-threatening arrhyth-
mias, and improve quality of life. Recent years ex-
perienced an increasing interest in home monitor-
ing, self-care and family support that are crucial for
achieving abovementioned therapeutic goals [4, 5].
Efforts of the investigators, and clinicians are fo-
cused on the optimal risk stratification of patients
who require more intensive treatment strategies,
and better selection of those in whom implanted
devices may prolong life [1, 2, 6, 7].
Stratification of risk in patients with HF is
based on plethora of clinical, laboratory and imag-
ing tests representing factors contributing to pro-
gression of a disease. Advanced age, coexisting
comorbidities like diabetes, renal dysfunction or
atrial fibrillation are the most significant covariates
influencing survival in HF patients [1, 2, 6, 8]. How-
ever, taking into account multitude of factors con-
tributing to HF progression it is unlikely than one
sole variable may indicate patients at poor progno-
sis. Therefore, attempts are being made to create
multivariate risk models that will provide better
estimation of individual patient’s risk. To facilitate
the clinical use of these models several risk scores
based on the results of multivariate analyses have
been created to predict mortality and HF progres-
sion [8–12].
The Seattle Heart Failure Model is the most
frequently used in clinical practice risk calculator
based on multi-parameter assessment for estima-
tion of 1-, 2- and 5-year mortality in HF patients.
This risk model was derived in a population of 1125
HF patients and validated in 5 other HF cohorts and
is based on simple clinical, pharmacological, labo-
ratory data and presence of an implanted device [9].
The risk calculator is available online (www.seattle-
heartfailuremodel.org) and then it is frequently used
in clinical practice. Nevertheless, this risk score,
published in 2006 is based on patients with predo-
minantly left ventricular (LV) systolic HF. Recent
years have experienced a significant improvement
in management of acute coronary syndromes and
consequently brought the change in the epidemio-
logy of HF population with an increasing number of
patients with preserved LV function. Even though
it was documented that this subpopulation carries
similar risk of mortality as typical systolic dysfunc-
tion, few studies addressed the problem of complex
risk stratification in these patients [10, 13, 14]. The
Spanish MUSIC study enrolled between 2003 and
2004 nearly 1000 ambulatory patients with mild to
moderate (II–III NYHA class) HF independently on
etiology, including patients with either depressed
or preserved LV function. The authors of this study
developed a risk score based on 10 clinical, echocar-
diographic, ECG and laboratory variables that were
independently associated with worse survival [10].
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Separate risk scores were developed to predict all-
cause mortality, cardiac death, sudden death or HF
progression. The prediction risk scores were test-
ed in the total MUSIC population as well as in sub-
groups of patients with preserved LV ejection frac-
tion (> 45%) which accounted for 25% of the total
population, and showed similar results in patients
with preserved and depressed LV function. Most
of risk prediction scores evaluate long term survi-
val; however the ability to predict survival up to one
year of follow up is gaining more and more atten-
tion as current guidelines for ICD/CRT-D implan-
tation recommend that the ability to survive in
a good functional status should be considered as one
of the selection criteria for a device implantation
[1, 7]. Several scores tested to predict one year sur-
vival in ICD/CRT recipients put emphasis on im-
portance of comorbidities, especially renal dysfunc-
tion in predicting survival [8, 9, 11, 12]. The study
by Goldenberg at al. [12] showed that a bedside cli-
nical risk score composed from 5 variables (NYHA
functional class > II, age > 70 years, blood urea
nitrogen > 26 mg/dL, QRS duration > 120 ms, and
atrial fibrillation) was able to identify patients who
are “too sick” or “too healthy” to benefit from ICD
implantation.
The study by Gomez de la Camara et al. [15],
published in the current issue of “Cardiology Jour-
nal”, follows the line of research in field of better
stratification of patients with HF, and confirms pre-
viously published results that underlined age, and
renal dysfunction, hyponatremia, and systolic dys-
function as the most significant variables associat-
ed with poor survival. The novelty of this manu-
script lies in a composition of a multivariate model
that includes not only commonly used clinical co-
variates but also psychosocial components, so fre-
quently omitted while looking at HF patient. The
authors retrospectively evaluated 600 patients ad-
mitted between 2003 and 2006 to three Spanish
hospitals for the first episode of HF. The final risk
score for predicting one year mortality included age,
serum creatinine and sodium levels, presence of
systolic dysfunction, and dependent basic daily ac-
tivities.
Even though it is also commonly known that
HF is associated not only with impaired physical
functional capacity and decreased quality of life, but
also with reduced ability to deal with daily life com-
mon tasks, assessment of patients autonomy has not
been included in multivariate risk models so far. It
should be emphasized that taking into consideration
expanding role of home-care and self-assessment,
patients autonomy in daily activities as well as so-
cial and family support have emerged as one of the
most important factors in management of HF. Pa-
tients with HF, frequently elderly, may experience
impairment in both basic activities of daily living
(ADL), such as ability to feed oneself, as well as in
instrumental ones which include those necessary
for involvement in more complex and community
related tasks. The relationship between impairment
in ADL and HF was demonstrated recently by Bowl-
ing et al. [16] who found that impairment of instru-
mental ADL in patients above 65 years old, yet with-
out HF, enrolled in the Cardiovascular Health Study
is a strong, and independent predictor of HF deve-
lopment and mortality during long term follow up.
Impairment of instrumental ADL defined as diffi-
culty with using telephone, preparing food, perform-
ing housework, managing finances and shopping
identified a group of patients at higher risk of HF
and all-cause mortality during the following
12-years observation. There is also data indicating
that dependence for basic an instrumental ADL is
strongly correlated with cognitive impairment and
contributes to increased mortality in HF patients
especially among elderly [17]. Social and family
support is known to be related with health-related
quality of life in HF patients and is considered as
an important factor in adherence to planned self-
care measures in HF like weight-measurement,
diuretic-adjustment, prescribed drug compliance.
Wu et al. [18] have shown that a combination of
medication adherence and social support, indepen-
dently or in combination were significantly related
to survival in HF patients. Impaired ADL and lack
of social support may therefore affect compliance
to prescribed medications which may consequent-
ly lead to deterioration of HF. It is hard to specu-
late whether this was a case in the population stud-
ied by Gomez de la Camara et al. [15]. However,
the other important fact should be emphasized —
the population presented in a manuscript by Gomez
de la Camara et al. [15], even though enrolled and
followed between 2003 and 2007 was significantly
undertreated. Beta-blockers were used in 31%, and
ACE inhibitors in 55% of patients. Similar inadher-
ence of common clinical practice into guidelines was
reported in 2003 based on EuroHeart Survey [19],
however, such a low percentage of patients treated
accordingly to current guidelines in period 2003–
2006 should be worrisome. Furthermore, the stud-
ied population consisted of very high proportion of
patients with preserved systolic function (75%)
therefore, whether this risk model could be applied
in patients with predominantly systolic dysfunction
remains questionable.
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The study by Gomez de la Camara et al. [15]
stresses the need to expand our thinking on risk
stratification and to treat HF patients in more ho-
listic way taking into consideration not only his
physical status but also psychosocial aspects of liv-
ing. Such an approach is in line with current guide-
lines that recommend multidisciplinary programs
which include patients’ education, optimal medical
treatment, psychosocial support and improved ac-
cess to heathcare system [1]. Patients should be
able to recognize and monitor signs and symptoms
of a disease, record daily weight and increase diu-
retic dose and/or alert theirs doctors in case of rap-
id weight gain. Adherence to prescribed medical
treatment and recommended diet and lifestyle are
essential in HF management. Recent years
brought also revolution in home monitoring of pa-
tients with implanted devices which are capable to
alert healthcare providers about any changes pre-
ceding the need of hospital readmission [3, 4].
Therefore, taking into consideration novel options
of HF management is seems that evaluation of psy-
chosocial factors and impairment of daily activities
may play more and more important role in HF
population.
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